This study reveals the critical role of HER2 and HER3 in regulating cell polarity in mucinous colorectal cancer, offering novel experimental design concepts for targeted therapy strategies in colorectal cancer, particularly providing valuable reference for research involving tumor microenvironment interactions.
Literature Overview
The article titled 'Signaling downstream of tumor–stroma interaction regulates mucinous colorectal adenocarcinoma apicobasal polarity,' published in Nature Communications, systematically investigates how tumor–stroma interactions regulate cell polarity via signaling pathways in mucinous colorectal cancer (MUC CRC). The study focuses on the mechanism of polarity reversal in tumor spheroids upon contact with the extracellular matrix (ECM), revealing a signaling axis involving α2β1-integrin, Src, SorLA, and HER2/HER3. By integrating patient-derived PDX models, single-cell analysis, and functional validation experiments, this work elucidates a novel pathway regulating cell polarity.Background Knowledge
Mucinous colorectal cancer (MUC CRC) is an aggressive subtype of colorectal cancer with poor prognosis, frequently presenting peritoneal metastasis and resistance to conventional chemotherapy. One of its hallmarks is the dissemination of tumor cells in inverted polarity (apical-out) spheroid configurations, a state strongly associated with adverse outcomes. Current understanding of the mechanisms governing polarity regulation remains limited, particularly regarding how signals from the tumor microenvironment reprogram cell polarity—a significant bottleneck in the field. Previous studies suggest potential involvement of TGF-β and Src pathways, yet the upstream sensors and downstream effectors remain unclear. This study investigates whether interactions between tumor cells and stromal collagen drive polarity reversal and systematically dissects the underlying molecular mechanisms. Using PDX models and organoid technology, the authors focus on integrin-mediated mechanotransduction and the crosstalk with receptor tyrosine kinase signaling, identifying SorLA as a key molecular hub.
Research Methods and Experiments
The authors utilized patient-derived mucinous colorectal cancer PDX models (PDX#1–#3) and primary patient-derived organoids (PDOs), culturing them under both suspension and collagen I-embedded conditions to mimic tumor states in fluid versus tissue environments. Immunofluorescence staining for Ezrin (apical marker) and F-actin, combined with a quantitative polarity scoring system, was used to assess polarity status. Single-cell mass cytometry analysis systematically compared integrin receptor expression profiles across models, revealing high expression of α2β1-integrin in PDX#3, which exhibited collagen-induced polarity reversal. Functional blockade using antibodies (AIIB2 and P1E6) against β1-integrin and α2-integrin confirmed their necessity in polarity reversal. Transcriptomic analysis and protein detection further showed that collagen-integrin binding activates Src and upregulates SorLA expression. siRNA and shRNA-mediated knockdown of SORL1 confirmed its essential role in β1-integrin recycling and polarity maintenance. In vivo, HER2/HER3-targeting antibodies (pertuzumab and trastuzumab) were applied to evaluate their impact on polarity, and clinical sample immunostaining analyzed the correlation between HER2, HER3, and SorLA expression.Key Conclusions and Perspectives
Research Significance and Prospects
This study comprehensively maps a complete signaling pathway for polarity regulation in mucinous colorectal cancer, from mechanical signal sensing to receptor recycling control, offering novel combinatorial drug targets (e.g., SorLA-integrin axis). Moreover, polarity status may serve as a potential biomarker for monitoring treatment response, especially when using HER2-targeted agents. Additionally, this mechanism may extend to other cancers exhibiting inverted polarity phenotypes, enhancing the generalizability of disease modeling.
Conclusion
This study uncovers a tumor–stroma interaction-driven polarity regulatory axis in mucinous colorectal cancer: collagen activates Src via α2β1-integrin, upregulates SorLA, which in turn promotes β1-integrin recycling and enhances HER2/HER3 signaling, ultimately determining cell polarity orientation. This finding not only deepens our understanding of MUC CRC metastasis mechanisms but also provides new perspectives for clinical intervention. Notably, HER2/HER3-targeted therapies are shown to reverse polarity and inhibit matrix remodeling, suggesting their potential role in altering the physical tumor microenvironment. From bench to bedside, this pathway may serve as a molecular marker for patient stratification, guiding the application of HER2-targeted therapies. Furthermore, SorLA, as a newly identified regulatory node, represents a promising candidate for future drug development. Overall, this work lays a crucial foundation for precision therapy and resistance mechanism studies in colorectal cancer, advancing the paradigm shift from static genomic analysis to dynamic microenvironment-responsive research.
